Cargando…
Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada
BACKGROUND: Administration of magnesium sulphate (MgSO(4)) to women with imminent preterm birth at <34 weeks is an evidence-based antenatal neuroprotective strategy to prevent cerebral palsy. Although a Society of Obstetricians and Gynaecologists of Canada (SOGC) national guideline with practice...
Autores principales: | Teela, Katherine C., De Silva, Dane A., Chapman, Katie, Synnes, Anne R., Sawchuck, Diane, Basso, Melanie, Liston, Robert M., von Dadelszen, Peter, Magee, Laura A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688933/ https://www.ncbi.nlm.nih.gov/pubmed/26694323 http://dx.doi.org/10.1186/s12884-015-0785-8 |
Ejemplares similares
-
Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis
por: Bickford, Celeste D, et al.
Publicado: (2013) -
MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)—implementation of a national guideline in Canada
por: De Silva, Dane A., et al.
Publicado: (2018) -
Antenatal magnesium sulphate administration for fetal neuroprotection: a French national survey
por: Chollat, Clément, et al.
Publicado: (2017) -
Determinants of magnesium sulphate use in women hospitalized at <29 weeks with severe or non-severe pre-eclampsia
por: De Silva, Dane A., et al.
Publicado: (2017) -
Availability and use of magnesium sulphate at health care facilities in two selected districts of North Karnataka, India
por: Katageri, Geetanjali, et al.
Publicado: (2018)